High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis

Pancreas

Volumn 43, Issue 1, 2014, Pages 135-140

  Cui, Xi Jun ^a   He, Qiang ^b   Zhang, Jian Min ^b   Fan, Hui Jie ^a,c   Wen, Zheng Fang ^d   Qin, Yan Ru ^b  

^a Wendeng Central Hospital   (China)

^b LINYI PEOPLE'S HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^d XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

aspirin; meta analysis; pancreatic cancer; risk

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG USE; HUMAN; LOW DRUG DOSE; META ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84891559641     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182a8d41f     Document Type: Article

References (37)

1. Inoue-Choi M, Flood A, Robien K, et al. Nutrients, food groups, dietary patterns, and risk of pancreatic cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2011;20:711-714.
2. Li D, Day RS, Bondy ML, et al. Dietary mutagen exposure and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:655-661. (Pubitemid 46650565)
3. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210. (Pubitemid 38339364)
4. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
5. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:47-55. (Pubitemid 41002838)
6. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603-1613. (Pubitemid 46710123)
7. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.
8. Tian W, Zhao Y, Liu S, et al. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev. 2010;19:288-298.
9. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev. 2007;26:525-534. (Pubitemid 350115125)
10. Telliez A, Furman C, Pommery N, et al. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Agents Med Chem. 2006;6:187-208. (Pubitemid 43796638)
11. Ali S, Banerjee S, Schaffert JM, et al. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J Cell Biochem. 2010;110:171-181.
12. Xu XF, Xie CG, Wang XP, et al. Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med. 2008;215:149-157.
13. Jacobs EJ, Connell CJ, Rodriguez C, et al. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst. 2004;96:524-528. (Pubitemid 38559576)
14. Anderson KE, Johnson TW, Lazovich D, et al. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst. 2002;94:1168-1171. (Pubitemid 34919054)
15. Tan XL, Reid-Lombardo KM, Bamlet WR, et al. Aspirin, nonsteroidal anti-inflammatory drugs (NSAID), acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res (Phila). 2011; 4:1835-1841.
16. Larsson SC, Giovannucci E, Bergkvist L, et al. Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:2561-2564. (Pubitemid 46048323)
17. Capurso G, Schunemann HJ, Terrenato I, et al. Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmacol Ther. 2007;26:1089-1099. (Pubitemid 47480965)
18. Bradley MC, Hughes CM, Cantwell MM, et al. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer. 2010;102:1415-1421.
19. Bonifazi M, Gallus S, Bosetti C, et al. Aspirin use and pancreatic cancer risk. Eur J Cancer Prev. 2010;19:352-354.
20. Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23:1403-1415.
21. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
22. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105-114. (Pubitemid 44937874)
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558. (Pubitemid 34746062)
24. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634. (Pubitemid 27387172)
25. Menezes RJ, Huber KR, Mahoney MC, et al. Regular use of aspirin and pancreatic cancer risk. BMC Public Health. 2002;2:18.
26. Friis S, Sorensen HT, McLaughlin JK, et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88:684-688. (Pubitemid 36411444)
27. Ratnasinghe LD, Graubard BI, Kahle L, et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004;24:3177-3184. (Pubitemid 39390970)
28. Schernhammer ES, Kang JH, Chan AT, et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst. 2004;96:22-28. (Pubitemid 38180956)
29. Fagard RH, Staessen JA, Thijs L. Advantages and disadvantages of the meta-analysis approach. J Hypertens Suppl. 1996;14:S9-S12.
30. Kim SR, Bae MK, Kim JY, et al. Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun. 2009;387:342-347.
31. Ghosh N, Chaki R, Mandal V, et al. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010;62:233-244.
32. Sclabas GM, Uwagawa T, Schmidt C, et al. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer. 2005;103:2485-2490. (Pubitemid 40800526)
33. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256-266.
34. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301-1309.
35. Orsini N, Bellocco R. Generalized least squares for trend estimation of summarized dose-response data. Stata J. 2006;6:40-57. (Pubitemid 43708443)
36. Rothwell PM,Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741-1750.
37. Hopewell S, Loudon K, Clarke MJ, et al. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev. 2009;MR000006.